2. UroToday Home
  3. Categories

nmCRPC COE

nmCRPC Outcomes in the Use of New Androgen Receptor Targeted Therapies - A Conversation with Charles Ryan and Alicia Morgans

nmCRPC Outcomes in the Use of New Androgen Receptor Targeted Therapies - A Conversation with Charles Ryan and Alicia Morgans

Details
(Length of Conversation: 24 min) Alicia Morgans and Charles Ryan discuss data that was presented at the ASCO GU 2018 meeting including two phase III trials, Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer ( SPARTAN ) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer ( PROSPER ) and the advances fo...
nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.

nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.

Details
(Length of Discussion: 16 min) Fred Saad and Alicia Morgans discuss results from A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER), as well as the endpoint of metastases free survival (MFS). It is exciting that early tr...
Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain

Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain

Details
(Length of Discussion: 22 min) Alicia Morgans and Maha Hussain discuss the Evaluating the Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER) phase III randomized double-blind controlled trial , in the nonmetastatic castration-resistant prostate cancer (nmCRPC) patient population which was first presented at the 2018 ASCO GU meeti...